About: The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease
Creator	Kim, Hyun Choi, Eun-Hye Kil, Hong Lim, Yeon
Source	Medline; PMC
abstract	Little is known about platelet dynamics and the effect of antiplatelet therapy in Kawasaki disease (KD). This study sought to define platelet activation dynamics in KD patients by assaying platelet-derived microparticles (PDMPs). We measured plasma PDMPs levels in 46 patients with KD using an enzyme-linked immunosorbent assay (ELISA). Blood samples were collected before, at 2–5 days, and 9–15 days after intravenous immunoglobulin (IVIG) infusion, 2 months and 4–5 months after the onset of KD. We measured PDMP levels in 23 febrile and 10 afebrile control patients. In the acute phase of KD patients, PDMP levels increased significantly after IVIG treatment (12.04 ± 5.58 nmol before IVIG infusion vs. 19.81 ± 13.21 nmol at 2–5 days after IVIG infusion, P = 0.006). PDMP levels were negatively correlated with age and positively correlated with procalcitonin levels in the acute phase of KD. No significant difference was found in PDMP levels between KD patients with and without coronary artery lesion (CAL). Elevated PDMP levels after IVIG therapy significantly decreased below the pre-IVIG level in subacute phase (19.81 ± 13.21 nmol at 2–5 days after IVIG infusion vs. 8.33 ± 2.02 nmol at 9–15 days after IVIG infusion, P < 0.001), and PDMP levels stayed below the pre-IVIG level in the convalescent phase, during which antiplatelet therapy was given. However, PDMP levels rebounded after discontinuing aspirin in 17 patients. In conclusion, enhanced platelet activation was noted before treatment of KD and peaked immediately after IVIG treatment. Recurrent rising of PDMP levels was observed after discontinuing aspirin, although there were no significant differences between the PDMP levels at 2 months after the onset of KD and those at 4–5 months after the onset of the disease.
has issue date	2017-05-26(xsd:dateTime)
bibo:doi	10.3346/jkms.2017.32.7.1147
bibo:pmid	28581272
has license	cc-by-nc
sha1sum (hex)	a3e2f4a9e9c1bc50381ef0161f062bb6f925b7be
schema:url	https://doi.org/10.3346/jkms.2017.32.7.1147
resource representing a document's title	The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease
has PubMed Central identifier	PMC5461319
has PubMed identifier	28581272
schema:publication	J Korean Med Sci
resource representing a document's body	covid:a3e2f4a9e9c1bc50381ef0161f062bb6f925b7be#body_text
is schema:about of	named entity 'LEVEL' named entity 'PATIENTS' named entity 'ANTIPLATELET THERAPY' named entity 'DIFFERENCE' named entity 'CONCLUSION' named entity 'FOUND' named entity 'PDMP' named entity 'COLLECTED' named entity 'AGE' named entity 'OBSERVED' named entity 'CORRELATED' named entity 'NOTED' named entity 'ONSET OF' named entity 'PLATELET' named entity 'NMOL' named entity 'AFEBRILE' named entity 'ENZYME-LINKED IMMUNOSORBENT ASSAY' named entity 'PLASMA' named entity 'GIVEN' named entity 'MEASURED' named entity 'SIGNIFICANT' named entity 'IVIG' named entity 'control' named entity 'onset' named entity 'observed' named entity 'afebrile' named entity 'Microparticle' named entity 'ANTIPLATELET THERAPY' named entity 'KAWASAKI DISEASE' named entity '0.001' named entity 'FEBRILE' named entity 'PEAKED' named entity 'ACUTE PHASE' named entity 'ASPIRIN' named entity 'LEVELS' named entity 'DECREASED' named entity 'USEFULNESS' named entity 'PLATELET-DERIVED MICROPARTICLE' named entity 'BIOMARKER' named entity 'STUDY' named entity 'PRE' named entity 'DAYS' named entity 'POSITIVELY CORRELATED' named entity 'INFUSION' named entity 'PHASE' named entity 'DERIVED' named entity 'MONTHS' named entity 'EFFECT' named entity 'KNOWN' named entity 'TREATMENT' named entity 'ELEVATED' named entity 'INCREASED' named entity 'ENHANCED' named entity 'PLATELET ACTIVATION' named entity 'USING' named entity 'BLOOD SAMPLES' named entity 'LITTLE' named entity 'DYNAMICS' named entity 'ABOUT' named entity '4-5' named entity 'CONTROL' named entity 'CORONARY ARTERY LESION' named entity 'INTRAVENOUS IMMUNOGLOBULIN' named entity 'RECURRENT' named entity 'DISEASE' named entity 'IMMEDIATELY' named entity 'KAWASAKI DISEASE' named entity 'PROCALCITONIN' named entity 'IVIG' named entity 'CONVALESCENT PHASE' named entity 'SUBACUTE' covid:arg/a3e2f4a9e9c1bc50381ef0161f062bb6f925b7be named entity 'patients' named entity 'infusion' named entity 'levels' named entity 'PDMPs' named entity 'enzyme-linked immunosorbent assay' named entity 'levels'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software